Search

Your search keyword '"Pope, Janet E."' showing total 1,069 results
Start Over Author "Pope, Janet E."
1,069 results on '"Pope, Janet E."'

53. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Author

Bergstra, Sytske Anne, primary, Sepriano, Alexandre, additional, Kerschbaumer, Andreas, additional, van der Heijde, Désirée, additional, Caporali, Roberto, additional, Edwards, Christopher John, additional, Verschueren, Patrick, additional, de Souza, Savia, additional, Pope, Janet E, additional, Takeuchi, Tsutomu, additional, Hyrich, Kimme L, additional, Winthrop, Kevin L, additional, Aletaha, Daniel, additional, Stamm, Tanja A, additional, Schoones, Jan W, additional, Smolen, Josef S, additional, and Landewé, Robert B M, additional

Published
2022
Full Text
View/download PDF

54. Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study

Author

Fortin, Paul R., primary, Neville, Carolyn, additional, Julien, Anne‐Sophie, additional, Rahme, Elham, additional, Haroun, Vinita, additional, Nimigon‐Young, Jodie, additional, Morrison, Anna‐Lisa, additional, Eng, Davy, additional, Peschken, Christine A., additional, Vinet, Evelyne, additional, Hudson, Marie, additional, Smith, Doug, additional, Matsos, Mark, additional, Pope, Janet E., additional, Clarke, Ann E., additional, Keeling, Stephanie, additional, Avina‐Zubieta, J. Antonio, additional, Rochon, Murray, additional, and Da Costa, Deborah, additional

Published
2022
Full Text
View/download PDF

55. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Author

Kerschbaumer, Andreas, primary, Sepriano, Alexandre, additional, Bergstra, Sytske Anne, additional, Smolen, Josef S, additional, van der Heijde, Désirée, additional, Caporali, Roberto, additional, Edwards, Christopher John, additional, Verschueren, Patrick, additional, de Souza, Savia, additional, Pope, Janet E, additional, Takeuchi, Tsutomu, additional, Hyrich, Kimme L, additional, Winthrop, Kevin L, additional, Aletaha, Daniel, additional, Stamm, Tanja A, additional, Schoones, Jan W, additional, and Landewé, Robert B M, additional

Published
2022
Full Text
View/download PDF

56. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Author

Smolen, Josef S, primary, Landewé, Robert B M, additional, Bergstra, Sytske Anne, additional, Kerschbaumer, Andreas, additional, Sepriano, Alexandre, additional, Aletaha, Daniel, additional, Caporali, Roberto, additional, Edwards, Christopher John, additional, Hyrich, Kimme L, additional, Pope, Janet E, additional, de Souza, Savia, additional, Stamm, Tanja A, additional, Takeuchi, Tsutomu, additional, Verschueren, Patrick, additional, Winthrop, Kevin L, additional, Balsa, Alejandro, additional, Bathon, Joan M, additional, Buch, Maya H, additional, Burmester, Gerd R, additional, Buttgereit, Frank, additional, Cardiel, Mario Humberto, additional, Chatzidionysiou, Katerina, additional, Codreanu, Catalin, additional, Cutolo, Maurizio, additional, den Broeder, Alfons A, additional, El Aoufy, Khadija, additional, Finckh, Axel, additional, Fonseca, João Eurico, additional, Gottenberg, Jacques-Eric, additional, Haavardsholm, Espen A, additional, Iagnocco, Annamaria, additional, Lauper, Kim, additional, Li, Zhanguo, additional, McInnes, Iain B, additional, Mysler, Eduardo F, additional, Nash, Peter, additional, Poor, Gyula, additional, Ristic, Gorica G, additional, Rivellese, Felice, additional, Rubbert-Roth, Andrea, additional, Schulze-Koops, Hendrik, additional, Stoilov, Nikolay, additional, Strangfeld, Anja, additional, van der Helm-van Mil, Annette, additional, van Duuren, Elsa, additional, Vliet Vlieland, Theodora P M, additional, Westhovens, René, additional, and van der Heijde, Désirée, additional

Published
2022
Full Text
View/download PDF

58. 2022 update

Author

Smolen, Josef S., Landewé, Robert B.M., Bergstra, Sytske Anne, Kerschbaumer, Andreas, Sepriano, Alexandre, Aletaha, Daniel, Caporali, Roberto, Edwards, Christopher John, Hyrich, Kimme L., Pope, Janet E., De Souza, Savia, Stamm, Tanja A., Takeuchi, Tsutomu, Verschueren, Patrick, Winthrop, Kevin L., Balsa, Alejandro, Bathon, Joan M., Buch, Maya H., Burmester, Gerd R., Buttgereit, Frank, Cardiel, Mario Humberto, Chatzidionysiou, Katerina, Codreanu, Catalin, Cutolo, Maurizio, Den Broeder, Alfons A., El Aoufy, Khadija, Finckh, Axel, Fonseca, João Eurico, Gottenberg, Jacques Eric, Haavardsholm, Espen A., Iagnocco, Annamaria, Lauper, Kim, Li, Zhanguo, McInnes, Iain B., Mysler, Eduardo F., Nash, Peter, Poor, Gyula, Ristic, Gorica G., Rivellese, Felice, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Stoilov, Nikolay, Strangfeld, Anja, Van Der Helm-Van Mil, Annette, Van Duuren, Elsa, Vliet Vlieland, Theodora P.M., Westhovens, René, Van Der Heijde, Désirée, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Comprehensive Health Research Centre (CHRC) - pólo NMS

Subjects
Arthritis, Rheumatoid, Biological Therapy, Rheumatology, Biochemistry, Genetics and Molecular Biology(all), Antirheumatic Agents, Immunology, Immunology and Allergy
Abstract

Funding Information: This study was funded by European League Against Rheumatism. Publisher Copyright: © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. Objectives: To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods: An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item. Results: The task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3-6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations. Conclusions: These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost. publishersversion published

Published
2022

61. Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2.

Author

Nikolic, Roko P. A., Pardo, Jordi Pardo, Pope, Janet E., Barber, Claire E. H., Barnabe, Cheryl, Schieir, Orit, Jamal, Shahin, Legge, Alexandra, Kuriya, Bindee, Akhavan, Pooneh, Thorne, J. Carter, Bombardier, Claire, Taylor-Gjevre, Regina, Bykerk, Vivian, Khraishi, Majed, Proulx, Laurie, Richards, Dawn P., Tugwell, Peter, Agarwal, Arnav, and Bansback, Nick

Published
2024
Full Text
View/download PDF

62. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

Author

Balanescu, Andra-Rodica, primary, Citera, Gustavo, additional, Pascual-Ramos, Virginia, additional, Bhatt, Deepak L, additional, Connell, Carol A, additional, Gold, David, additional, Chen, All-Shine, additional, Sawyerr, Gosford, additional, Shapiro, Andrea B, additional, Pope, Janet E, additional, and Schulze-Koops, Hendrik, additional

Published
2022
Full Text
View/download PDF

63. Canadian Rheumatology Association Living Guidelines for the Pharmacological Management of Rheumatoid Arthritis With Disease-Modifying Antirheumatic Drugs

Author

Hazlewood, Glen S., primary, Pardo, Jordi Pardo, additional, Barnabe, Cheryl, additional, Schieir, Orit, additional, Barber, Claire E.H., additional, Proulx, Laurie, additional, Richards, Dawn P., additional, Tugwell, Peter, additional, Bansback, Nick, additional, Akhavan, Pooneh, additional, Bombardier, Claire, additional, Bykerk, Vivian, additional, Jamal, Shahin, additional, Khraishi, Majed, additional, Taylor-Gjevre, Regina, additional, Thorne, J. Carter, additional, Agarwal, Arnav, additional, and Pope, Janet E., additional

Published
2022
Full Text
View/download PDF

64. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria

Author

Johnson, Sindhu R., Naden, Raymond P., Fransen, Jaap, van den Hoogen, Frank, Pope, Janet E., Baron, Murray, Tyndall, Alan, Matucci-Cerinic, Marco, Denton, Christopher P., Distler, Oliver, Gabrielli, Armando, van Laar, Jacob M., Mayes, Maureen, Steen, Virginia, Seibold, James R., Clements, Phillip, Medsger, Thomas A., Jr., Carreira, Patricia E., Riemekasten, Gabriela, Chung, Lorinda, Fessler, Barri J., Merkel, Peter A., Silver, Richard, Varga, John, Allanore, Yannick, Mueller-Ladner, Ulf, Vonk, Madelon C., Walker, Ulrich A., Cappelli, Susanna, and Khanna, Dinesh

Published
2014
Full Text
View/download PDF

67. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Author

Khanna, Dinesh, Denton, Christopher P, Lin, Celia J F, van Laar, Jacob M, Frech, Tracy M, Anderson, Marina E, Baron, Murray, Chung, Lorinda, Fierlbeck, Gerhard, Lakshminarayanan, Santhanam, Allanore, Yannick, Pope, Janet E, Riemekasten, Gabriela, Steen, Virginia, Müller-Ladner, Ulf, Spotswood, Helen, Burke, Laura, Siegel, Jeffrey, Jahreis, Angelika, and Furst, Daniel E

Published
2018
Full Text
View/download PDF

69. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort

Author

Mihai, Carina, Antic, Milos, Dobrota, Rucsandra, Bonderman, Diana, Chadha-Boreham, Harbajan, Coghlan, John Gerry, Denton, Christopher P, Doelberg, Martin, Grünig, Ekkehard, Khanna, Dinesh, McLaughlin, Vallerie V, Müller-Ladner, Ulf, Pope, Janet E, Rosenberg, Daniel M, Seibold, James R, Vonk, Madelon C, and Distler, Oliver

Published
2018
Full Text
View/download PDF

73. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial

Author

Matteson, Eric L, Kelly, Clive, Distler, Jörg H W, Hoffmann-Vold, Anna Maria, Seibold, James R, Mittoo, Shikha, Dellaripa, Paul F, Aringer, Martin, Pope, Janet E, Distler, Oliver, James, Alexandra, Schlenker-Herceg, Rozsa, Stowasser, Susanne, Quaresma, Manuel, Flaherty, Kevin R, and University of Zurich

Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine, 610 Medicine & health
Published
2022
Full Text
View/download PDF

77. Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up

Author

Seibold, James R., Wigley, Fredrick M., Schiopu, Elena, Denton, Christopher P., Silver, Richard M., Steen, Virginia D., Domsic, Robyn, Medsger, Thomas A., Jr, Mayes, Maureen D., Chatterjee, Soumya, Chung, Lorinda, Csuka, Mary Ellen, Khanna, Dinesh, Collier, David, Frech, Tracy M., Molitor, Jerry A., Rothfield, Naomi, Herrick, Ariane L., Simms, Robert, Pope, Janet E., Baron, Murray, Hsu, Vivien M., Peng, Stanford L., Spiera, Robert, Fessler, Barri J., Kahaleh, Bashar, Varga, John, Laliberte, Kevin, Wade, Michael, and Rollins, Kristan

Published
2017
Full Text
View/download PDF

80. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.

Author

Kerschbaumer, Andreas, Sepriano, Alexandre, Bergstra, Sytske Anne, Smolen, Josef S., van der Heijde, Désirée, Caporali, Roberto, Edwards, Christopher John, Verschueren, Patrick, de Souza, Savia, Pope, Janet E., Takeuchi, Tsutomu, Hyrich, Kimme L., Winthrop, Kevin L., Aletaha, Daniel, Stamm, Tanja A., Schoones, Jan W., and Landewé, Robert B. M.

Abstract

Objectives: To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of rheumatoid arthritis (RA).Methods: This systematic literature review (SLR) investigated the efficacy of conventional synthetic (cs), biological (b), biosimilar and targeted synthetic (ts)DMARDs in patients with RA. Medline, EMBASE, Cochrane CENTRAL and Web of Science were used to identify all relevant articles published since the previous update in 2019 to 14 January 2022.Results: Of 8969 search results, 169 articles were selected for detailed review and 47 were finally included. Trials investigated the efficacy of csDMARDs, bDMARDs and tsDMARDs, DMARD switching, tapering and trials investigating different treatment strategies. The compounds investigated were csDMARDs (methotrexate (MTX), leflunomide, sulfasalazine, hydroxychloroquine), bDMARDs (abatacept, adalimumab, certolizumab-pegol, denosumab, etanercept, infliximab, levilimab, olokizumab, opineracept, rituximab, sarilumab, tocilizumab) and tsDMARDs (baricitinib, filgotinib, tofacitinib, upadacitinib). The efficacy of csDMARDs+ short-term glucocorticoids in early RA was confirmed and similar to bDMARD+MTX combination therapy. Interleukin-6 pathway inhibition was effective in trials on olokizumab and levilimab. Janus kinase inhibitor (JAKi) was efficacious in different patient populations. After insufficient response to JAKi, patients could respond to TNFi treatment. Tapering of DMARDs was feasible for a proportion of patients, who were able to taper therapy while remaining in low disease activity or remission.Conclusion: The results of this SLR, together with one SLR on safety of DMARD and one on glucocorticoids, informed the taskforce of the 2022 update of the EULAR recommendations for pharmacological management of RA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

81. Medical cannabis use by rheumatology patients in routine clinical care: results from The Ontario Best Practices Research Initiative

Author

Rampakakis, Emmanouil, primary, Thorne, Carter, additional, Cesta, Angela, additional, Movahedi, Mohammad, additional, Li, XiuYing, additional, Mously, Carol, additional, Ahluwalia, Vandana, additional, Brophy, Julie, additional, Ciaschini, Patricia, additional, Keystone, Edward, additional, Lau, Arthur, additional, Major, Gerald, additional, Pavlova, Viktoria, additional, Pope, Janet E., additional, and Bombardier, Claire, additional

Published
2022
Full Text
View/download PDF

82. Results From the 2020 Canadian Rheumatology Association’s Workforce and Wellness Survey

Author

Kulhawy-Wibe, Stephanie C., primary, Widdifield, Jessica, additional, Lee, Jennifer J.Y., additional, Thorne, J. Carter, additional, Yacyshyn, Elaine A., additional, Batthish, Michelle, additional, Jerome, Dana, additional, Shupak, Rachel, additional, Jilkine, Konstantin, additional, Purvis, Jane, additional, Shamis, Justin, additional, Roberts, Janet, additional, Kur, Jason, additional, Burt, Jennifer E., additional, Johnson, Nicole A., additional, Barnabe, Cheryl, additional, Hartfeld, Nicole M.S., additional, Harrison, Mark, additional, Pope, Janet E., additional, and Barber, Claire E.H., additional

Published
2022
Full Text
View/download PDF

85. 1501 Genetics of age at systemic lupus erythematosus diagnosis

Author

Carlomagno, Raffaella, primary, Liao, Fangming, additional, Cao, Jingjing, additional, Dominguez, Daniela, additional, Gladman, Dafna D, additional, Ishimori, Mariko, additional, Jefferies, Caroline, additional, Kamen, Diane L, additional, Kamphuis, Sylvia, additional, Klein-Gitelman, Marisa S, additional, Knight, Andrea M, additional, Lee, Chia-Chi J, additional, Levy, Deborah M, additional, Onel, Karen B, additional, Paterson, Andrew D, additional, Peschken, Christine A, additional, Pope, Janet E, additional, Touma, Zahi, additional, Urowitz, Murray B, additional, Wallace, Daniel J, additional, Webber, Declan, additional, Wither, Joan E, additional, Silverman, Earl D, additional, and Hiraki, Linda T, additional

Published
2021
Full Text
View/download PDF

91. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis

Author

Hazlewood, Glen S, Thorne, J Carter, Pope, Janet E, Lin, Daming, Tin, Diane, Boire, Gilles, Haraoui, Boulos, Hitchon, Carol A, Keystone, Edward C, Jamal, Shahin, Bykerk, Vivian P, Khraishi, Majed, Villeneuve, Edith, Baron, Murray, Colmegna, Ines, Bartlett, Susan, Zummer, Michel, Akhavan, Pooneh, Rubin, Lawrence, Kuriya, Bindee, Ahluwahlia, Vandana, Bensen, William, Larche, Maggie, Barra, Lillian, Nair, Bindu, Penney, Christopher, Mosher, Dianne, Barnabe, Cheryl, Arbillaga, Hector, Lyddell, Christopher, Klinkhoff, Alice, Sniderman, Franci, Wang, Jim, and Scientific, McDougall

Published
2016
Full Text
View/download PDF

94. Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis.

Author

Zheng, Boyang, Wang, Mianbo, McKenna, Kerry, Shapiro, Lee, Silver, Richard, Csuka, Mary Ellen, van den Hoogen, Frank, Robinson, David, Pauling, John D., Hummers, Laura, Krieg, Thomas, Del Galdo, Francesco, Spiera, Robert, Jones, Niall, Khalidi, Nader, Vacca, Alessandra, de Vries‐Bouwstra, Jeska K., Gordon, Jessica, Baron, Murray, and Pope, Janet E.

Abstract

Objective: Diffuse cutaneous systemic sclerosis (SSc) is a highly heterogeneous disease. A provisionally approved Composite Response Index in diffuse cutaneous SSc (CRISS) was developed as a 1‐year outcome measure for clinical trials. Our goal was to further validate the CRISS by examining agreement between CRISS definitions for improved/non‐improved with physicians' evaluation of disease. Methods: Patient profiles from a large observational cohort were created for 50 random diffuse cutaneous SSc patients of <5 years disease duration with improved CRISS scores after 1 year and 50 with non‐improved CRISS scores. Profiles described disease features used during the initial CRISS development at baseline and at 1 year. Each profile was independently rated by 3 expert physicians. Majority opinion determined whether a patient was improved or not improved, and kappa agreement with the CRISS cutoff of 0.6 was calculated. Results: Patients had mean ± SD disease duration of 2.2 ± 1.3 years. There was substantial agreement between the physician majority opinion about each case and the CRISS (κ = 0.76 [95% confidence interval (95% CI) 0.64–0.88]). The agreement between each individual physician opinion and the CRISS was also substantial (κ = 0.70 [95% CI 0.62–0.78]). All CRISS non‐improvers were also rated as non‐improved by physician majority; however, 12 CRISS improvers were rated as non‐improved by physicians. Conclusion: There was substantial agreement between the dichotomous CRISS rating and physician assessment of diffuse cutaneous SSc patients after 1 year. This supports the use of a CRISS cutoff at 0.6 for improvement versus non‐improvement, although the CRISS tended to rate more patients as improved than did physicians. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

95. “From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)

Author

Bartlett, Susan J., primary, Bykerk, Vivian P., additional, Schieir, Orit, additional, Valois, Marie-France, additional, Pope, Janet E, additional, Boire, Gilles, additional, Hitchon, Carol, additional, Hazlewood, Glen, additional, Bessette, Louis, additional, Keystone, Edward, additional, Thorne, Carter, additional, Tin, Diane, additional, and Bingham, Clifton O, additional

Published
2021
Full Text
View/download PDF

96. Measuring the Impact of MyLupusGuidein Canada: Results of a Randomized Controlled Study

Author

Fortin, Paul R., Neville, Carolyn, Julien, Anne‐Sophie, Rahme, Elham, Haroun, Vinita, Nimigon‐Young, Jodie, Morrison, Anna‐Lisa, Eng, Davy, Peschken, Christine A., Vinet, Evelyne, Hudson, Marie, Smith, Doug, Matsos, Mark, Pope, Janet E., Clarke, Ann E., Keeling, Stephanie, Avina‐Zubieta, J. Antonio, Rochon, Murray, and Da Costa, Deborah

Abstract

This study was undertaken to assess the effects of a web‐based program, MyLupusGuide,developed to facilitate self‐management in systemic lupus erythematosus (SLE). In this randomized controlled online study, participants received either immediate access to the MyLupusGuide site or delayed access starting on month 3. The primary outcome was the patient activation measure (PAM) score. Secondary outcomes included measurements of health status, self‐efficacy, coping, perceived patient–physician relationship, and medication adherence. Outcomes were measured at the baseline visit and at the 3‐month and 6‐month follow‐up visits. We used linear mixed modeling to compare PAM scores between the 2 groups at months 3 and 6. There were 541 participants included in this study. The mean ± SE age was 50 ± 14 years; 93% were female and 74% were White. The mean ± SE disease duration was 17 ± 12 years, and 56% visited MyLupusGuide at least once. The baseline mean ± SE PAM score was 61.2 ± 13, with 36% scoring low for perceived self‐management skills. After 3 months of exposure to MyLupusGuide, there were no differences in terms of PAM scores between groups. In exploratory analyses, we found significant improvement in PAM scores in those who had low PAM scores at baseline and in male individuals. We observed significant improvements in self‐efficacy before and after access to MyLupusGuide and delayed improvements at month 6 compared to month 3 in terms of mental health and emotional coping. MyLupusGuide increases self‐efficacy but not patient activation. A total of 56% of participants visited the MyLupusGuide site during the study period. Individuals with lupus need support to become activated toward self‐management behaviors.

Published
2023
Full Text
View/download PDF

97. sj-docx-1-jso-10.1177_23971983211000971 – Supplemental material for Immunosuppression use in early systemic sclerosis may be increasing over time

Author

Park, Ryan, Nevskaya, Tatiana, Baron, Murray, and Pope, Janet E

Subjects
110322 Rheumatology and Arthritis, FOS: Clinical medicine, humanities
Abstract

Supplemental material, sj-docx-1-jso-10.1177_23971983211000971 for Immunosuppression use in early systemic sclerosis may be increasing over time by Ryan Park, Tatiana Nevskaya, Murray Baron and Janet E Pope in Journal of Scleroderma and Related Disorders

Published
2021
Full Text
View/download PDF

98. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Author

Nash, Peter, Kerschbaumer, Andreas, Dörner, Thomas, Dougados, Maxime, Fleischmann, Roy M, Geissler, Klaus, McInnes, Iain, Pope, Janet E, van der Heijde, Désirée, Stoffer-Marx, Michaela, Takeuchi, Tsutomu, Trauner, Michael, Winthrop, Kevin L, de Wit, Maarten, Aletaha, Daniel, Baraliakos, Xenofon, Boehncke, Wolf-Henning, Emery, Paul, Isaacs, John D, Kremer, Joel, Lee, Eun Bong, Maksymowych, Walter P, Voshaar, Marieke, Tam, Lai-Shan, Tanaka, Yoshiya, van den Bosch, Filip, Westhovens, René, Xavier, Ricardo, and Smolen, Josef S

Subjects
Rheumatoid/drug therapy/immunology, Piperidines/therapeutic use, Advisory Committees, Antirheumatic Agents/therapeutic use, Psoriasis/drug therapy/immunology, Azetidines/therapeutic use, Psoriatic/drug therapy/immunology, Cytokines/immunology, Pyrazoles/therapeutic use, Drug Therapy, Rheumatology, Heterocyclic Compounds, Humans, Purines/therapeutic use, Pyridines/therapeutic use, ddc:616, Adamantane/analogs & derivatives/therapeutic use, Arthritis, Janus Kinase Inhibitors/therapeutic use, Inflammatory Bowel Diseases/drug therapy/immunology, Pyrimidines/therapeutic use, Sulfonamides/therapeutic use, Europe, Combination, 3-Ring/therapeutic use, Niacinamide/analogs & derivatives/therapeutic use, Spondylarthropathies/drug therapy/immunology, Ankylosing/drug therapy/immunology, Triazoles/therapeutic use, Spondylitis
Abstract

Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.

Published
2021

99. Healthcare utilization and economic burden in systemic sclerosis: a systematic review.

Author

Calderon, Leonardo Martin, Chaudhury, Mitali, and Pope, Janet E

Subjects
META-analysis, MEDICAL information storage & retrieval systems, SYSTEMATIC reviews, SYSTEMIC scleroderma, MEDICAL care costs, MEDICAL care use, DESCRIPTIVE statistics, ECONOMIC aspects of diseases, DATA analysis software, MEDLINE
Abstract

Objective Systemic sclerosis (SSc) is characterized by vasculopathy, fibrosis of skin and internal organs, and autoimmunity with complications including interstitial lung disease, pulmonary hypertension, and digital ulcers with substantial morbidity and disability. Patients with SSc may require considerable healthcare resources with economic impact. The purpose of this systematic review was to provide a narrative synthesis of the economic impact and healthcare resource utilization associated with SSc. Methods MEDLINE and EMBASE were searched from inception to 20 January 2021. Studies were included if they provided information regarding the total, direct and indirect cost of SSc. The cost of SSc subtypes and associated complications was determined. Risk of bias assessments through the Joanna Briggs Institute cross-sectional and case series checklists, and the Newcastle–Ottawa Cohort and Case–Control study scales were performed. A narrative synthesis of included studies was planned. Results The number of publications retrieved was 1778, of which 34 were included representing 20 cross-sectional, 11 cohort, and three case–control studies. Studies used various methods of calculating cost including prevalence-based cost-of-illness approach and health resource units cost analysis. Overall SSc total annual cost ranged from USD $14 959 to $23 268 in USA, CAD $10 673 to $18 453 in Canada, €4607 to €30 797 in Europe, and AUD $7060 to $11 607 in Oceania. Annual cost for SSc-associated interstitial lung disease and pulmonary hypertension was USD $31 285–55 446 and $44 454–63 320, respectively. Conclusion Cost-calculation methodology varied greatly between included studies. SSc represents a significant patient and health resource economic burden. SSc-associated complications increase economic burden and are variable depending on geographical location and access. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results